Try Mental Wellness – Lifestyle
Author:
Tempest Therapeutics
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
April 29, 2026
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
April 22, 2026
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
April 14, 2026
Tempest Reports Year End 2025 Financial Results and Provides Business Update
March 30, 2026
Tempest Reports Year End 2025 Financial Results and Provides Business Update
March 30, 2026
Tempest Therapeutics Announces Up To $6 Million Private Placement
March 23, 2026
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
March 11, 2026